Allie LogoA Search Service for Abbreviation / Long Form

■略語／展開語 : mut／mutation

関連PubMed/MEDLINE情報

合計出現文献数:

50

略語:

mut

(

>>共起略語

)

展開形:

mutation

(アミノ残基の) 置換変異, ミューテーション, 人工置換, 変異, 突然変異

mut (35)回

MUT (15)回

mutations (25)回

mutation (22)回

mutational (1)回

Mutation (1)回

Mutations (1)回

mut / mutations (20)回

mut / mutation (13)回

MUT / mutation (9)回

MUT / mutations (5)回

mut / Mutation (1)回

mut / mutational (1)回

MUT / Mutations (1)回

No.
発表年
題目
共起略語

1

2025

Durvalumab with or without tremelimumab in combination with chemotherapy in first-line metastatic non-small-cell lung cancer: outcomes by tumor mutational burden in POSEIDON.
Mb, OS, PD-L1, TC, TMB, bTMB, mNSCLC, tTMB

2

2025

Leveraging TME features and multi-omics data with an advanced deep learning framework for improved Cancer survival prediction.
CNV, GBM, LGG, MIC

3

2024

Comprehensive genomic profiling of ESR1, PIK3CA, AKT1, and PTEN in HR(+)HER2(-) metastatic breast cancer: prevalence along treatment course and predictive value for endocrine therapy resistance in real-world practice.
CGP, GA, MBC, PTENloss, TF, rwPFS

4

2024

KRASG12D-Mutated Metastatic Colorectal Cancer: Clinical, Molecular, Immunologic, and Prognostic Features of a New Emerging Targeted Alteration.
BEV, mCRC, wt

5

2024

Negative Hyperselection of Resistance Mutations for Panitumumab Maintenance in RAS Wild-Type Metastatic Colorectal Cancer (PanaMa Phase II Trial, AIO KRK 0212).
CI, FAS, HR, NGS, ORR, OS, PFS, WT, mCRC

6

2024

Outcomes in biomarker-selected subgroups from the KESTREL study of durvalumab and tremelimumab in recurrent or metastatic head and neck squamous cell carcinoma.
Mb, NLR, ORRs, OS, PD-L1, TC, bTMB

7

2024

Pan-cancer analysis of CDKN2A alterations identifies a subset of gastric cancer with a cold tumor immune microenvironment.
ALT, ICIs, ICIs, OS, WT, del

8

2024

Prognostic importance of prognostic nutritional index and modified Glasgow prognostic score in advanced lung cancer with targetable mutation.
PNI, mGPS

9

2024

The long and winding road to biomarkers for immunotherapy: a retrospective analysis of samples from patients with triple-negative breast cancer treated with pembrolizumab.
GARP, ICB, Mb, PD-L1, TILs, TMB, TNBC

10

2024

Treatment outcome according to genetic tumour alterations and clinical characteristics in digestive high-grade neuroendocrine neoplasms.
HG-NEN, NEC

11

2024

TTBK2 T3290C mutation in spinocerebellar ataxia 11 interferes with ciliogenesis.
SCA11

12

2023

A prognostic estimation model based on mRNA-sequence data for patients with oligodendroglioma.
CGGA, DEmRNAs, IDH, LASSO, PRS

13

2023

Multiple PIK3CA mutation clonality correlates with outcomes in taselisib + fulvestrant-treated ER+/HER2-, PIK3CA-mutated breast cancers.
PI3K, RTK, ctDNA

14

2023

Outcome of First-Line Treatment With Pembrolizumab According to KRAS/TP53 Mutational Status for Nonsquamous Programmed Death-Ligand 1-High (≥50%) NSCLC in the German National Network Genomic Medicine Lung Cancer.
HR, TME, WT

15

2022

Effects of TP53 Mutations and miRs on Immune Responses in the Tumor Microenvironment Important in Pancreatic Cancer Progression.
GOF, PDAC

16

2022

Melanoma-specific survival before and after inclusion in a familialmelanoma dermatologic surveillance program in CDKN2A mutation carriers and non-carriers.
WT

17

2022

Molecular Profiling of Well-Differentiated Neuroendocrine Tumours: The Role of ctDNA in Real-World Practice.
PAs, WDNETs, ctDNA, mMAF

18

2021

A mutation in desmin makes skeletal muscle less vulnerable to acute muscle damage after eccentric loading in rats.
WT

19

2021

Genetic Determinants of Outcome in Intrahepatic Cholangiocarcinoma.
CDKN2A, IDH1, OS, TP53, iCCA

20

2021

Genomic complexity is associated with epigenetic regulator mutations and poor prognosis in diffuse large B-cell lymphoma.
DLBCL

Rows per page:

1–20 of 50